In addition, accounting to the official website of CStone Pharmaceuticals, they retained the ADCP of an approved anti-PD-L1 antibody (Sugemalimab), to induce direct tumor killing by macrophages and enhance tumor antigen presentation for long-term anti-tumor immunity. This evidence concerns the gene CD274 and neoplasm.